News
Baron Health Care Fund stated the following regarding AstraZeneca PLC (NASDAQ:AZN) in its Q4 2024 investor letter: "Poor ...
AstraZeneca PLC (NASDAQ:AZN)’s Q4 2024 financial results highlight robust growth despite some challenges. Total revenue for the year increased by 21%, driven by strong performances across all ...
Second, thanks to the progress of our collaboration with AstraZeneca. Up to year-end 2024, $47 million have been paid to Cellectis under the joint research and collaboration agreement of which $25 ...
Reports Q4 revenue $1.99M vs $33.22M last year. “2024 has been an important year for Cellectis (CLLS): we are now developing three programs in collaboration with AstraZeneca (AZN). So far ...
Cellectis demonstrated robust performance in Q4 2024, significantly outperforming market expectations. The company’s strategic initiatives, including its partnership with AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results